Adlai Nortye Biopharma
Wei HE has worked in the field of biopharma and pharmaceutical research since 2003. Wei began their career as a Research Assistant at the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, China, where they obtained their Master's degree in 2011. During this time, they conducted research in metal catalysis and participated in several R&D projects. In 2016, they moved to Nanyang Technological University as a Research Assistant. In 2017, they joined Flamma SpA as the R&D Manager at Flamma Honkai (Dalian) Pharmaceutical Co., Ltd. where they were responsible for process development, customer communication, team training, and lab management. In 2021, they were appointed as Director in CMC at Adlai Nortye Biopharma Co., Ltd.
Wei HE has an extensive educational background. Wei obtained their Bachelor's Degree in Chemistry from Lanzhou University in 2003. Wei then went on to receive their Master's Degree in Organic Chemistry from the University of Chinese Academy of Sciences in 2011. Finally, they completed their Doctor of Philosophy (Ph.D.) in Chemistry from Nanyang Technological University Singapore in 2016. Additionally, they hold a LICENCE/CERTIFICATE ISSUED UNDER THE RADIATION PROTECTION ACT from the SINGAPORE National Environment Agency.
Adlai Nortye Biopharma
1 followers
Adlai Nortye Biopharma is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, they have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. They have assembled a world-class management team, built a unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.